Select country set
language
Menu Shopping cart 0,00 Search
Distributed product

Urine CrossLaps® (CTX-I) EIA

  • Regulatory status:RUO
  • Type:Competitive ELISA
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New AC-03F1 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Competitive ELISA

Applications

Urine

Sample Requirements

15 µl/well

Shipping

Shipped on ice packs. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Range

75 - 6750 ng/ml

Limit of Detection

50 ng/ml

Intra-assay (Within-Run)

n = 25
CV = 6.8%

Inter-assay (Run-to-Run)

n = 5
CV = 4.4%

Spiking Recovery

96%

Dilution Linearity

101%

Summary

Features

European Union: for in vitro diagnostic use

Rest of the world: for research use only!

The total assay time is less than 2.5 hours

The kit measures degradation products of C-terminal telopeptides of Type-I collagen in human urine

Assay format is 96 wells

Quality Controls are human serum based

Standards are recombinant protein based
Components of the kit are provided ready to use or concentrated

Research topic

Bone and cartilage metabolism

Summary

The Urine CrossLaps® EIA is an enzyme immunosorbent assay for quantitative determination of degradation products of C-terminal telopeptides of Type-I collagen in human urine. The Urine CrossLaps® EIA assay is intended for in vitro diagnostic use as an indication of human bone resorption and may be used as an aid in:

A. Monitoring bone resorption changes of

  1. Anti-resorptive therapies in postmenopausal women: a) Hormone Replacement Therapies (HRT) with hormones and hormone like drugs b) Bisphosphonate therapies
  2. Anti-resorptive therapies in individuals diagnosed with osteopenia: a) Hormone Replacement Therapies (HRT) with hormones and hormone like drugs b) Bisphosphonate therapies
    B. Predicting skeletal response (Bone Mineral Density) in postmenopausalwomen undergoing anti-resorptive therapies: a) Hormone Replacement Therapies (HRT) with hormones and hormone like drugs b) Bisphosphonate therapies
Related Products Docs